's Avatar

@sabian-eldritch.bsky.social

10 Followers  |  28 Following  |  5 Posts  |  Joined: 13.11.2024
Posts Following

Posts by (@sabian-eldritch.bsky.social)

I know nothing about Lost but that's never stopped me before.

14.03.2025 22:53 — 👍 3    🔁 0    💬 0    📌 0
My LOST Theory that Makes Sense and Ties it All Together (90 Minutes)
YouTube video by TheBurgerkrieg My LOST Theory that Makes Sense and Ties it All Together (90 Minutes)

www.youtube.com/watch?v=51Mu...
I promise you, you have not heard this LOST theory before

14.03.2025 19:58 — 👍 43    🔁 68    💬 10    📌 6

Its comforting to see charity around these topics still have support even with things being what they are.

13.02.2025 02:00 — 👍 2    🔁 0    💬 0    📌 0
Post image

Customized my desktop with art of my late beloved.

19.01.2025 08:42 — 👍 2    🔁 0    💬 0    📌 0
Two years after starting treatment, about 92% of trial participants randomly assigned to the nivolumab–AVD group were alive without their cancer starting to grow again—a measure known as progression-free survival—compared with 83% in the brentuximab–AVD group. People in the nivolumab–AVD group also had fewer side effects overall and fewer serious side effects, according to findings reported October 17 in the New England Journal of Medicine.

Two years after starting treatment, about 92% of trial participants randomly assigned to the nivolumab–AVD group were alive without their cancer starting to grow again—a measure known as progression-free survival—compared with 83% in the brentuximab–AVD group. People in the nivolumab–AVD group also had fewer side effects overall and fewer serious side effects, according to findings reported October 17 in the New England Journal of Medicine.

The immunotherapy drug nivolumab (Opdivo) should be part of the initial treatment of teens and adults with advanced forms of classic Hodgkin lymphoma, according to updated results from a large NCI-funded clinical trial. 

In the nearly 1,000-patient trial, treatment with nivolumab and a three-drug chemotherapy regimen called AVD was better at eliminating cancer and keeping it at bay than the current standard initial treatment for the disease, AVD combined with the targeted therapy brentuximab (Adcetris).

The immunotherapy drug nivolumab (Opdivo) should be part of the initial treatment of teens and adults with advanced forms of classic Hodgkin lymphoma, according to updated results from a large NCI-funded clinical trial. In the nearly 1,000-patient trial, treatment with nivolumab and a three-drug chemotherapy regimen called AVD was better at eliminating cancer and keeping it at bay than the current standard initial treatment for the disease, AVD combined with the targeted therapy brentuximab (Adcetris).

I always said “this is the best year so far in human history to get cancer” and John retorted, “yeah, but next year would have been better.”

Truly ridiculous how right he was…

13.01.2025 04:00 — 👍 5103    🔁 156    💬 76    📌 9

Yeah a bit. I figured it was just the remnants of my dreams trying to play in my head. I never really remember my dreams all that well though.

13.11.2024 01:16 — 👍 0    🔁 0    💬 0    📌 0

What's this tuberculosis. Is it a type of tuber./s

13.11.2024 00:43 — 👍 0    🔁 0    💬 0    📌 0